Prolor Biotech reported positive results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults. The findings show that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth hormone (hGH), and further validates the dosing regimen for the company’s planned Phase III trial. In the Phase II clinical trial, hGH-CTP was administered to growth hormone deficient adults for a period of four weeks.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

A Promising Treatment For Trauma-Induced Fibromyalgia
March 23, 2023

Generative AI Startup Helps Developers Test Code Logic
March 23, 2023

Cream Cheese And Cheddar Cheese – Made From Chickpeas
March 22, 2023

$8M For Startup That Digitizes The Construction Supply Chain
March 22, 2023
Facebook comments